Bilastine is a white to off-white crystalline powder that is sparingly soluble in methylene chloride and practically insoluble in acetone. It has an assay range of 98.0% to 102.0%.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals proudly presents Carbocisteine Lysine salt monohydrate, a meticulously crafted mucolytic agent essential for healthcare professionals treating patients with respiratory tract disorders. This fine, white to slightly yellow powder exhibits high-quality performance, designed to alleviate conditions like chronic bronchitis, COPD, pneumonia, and cystic fibrosis through its ability to degrade thick, viscous mucus, facilitating easier expectoration and promoting respiratory comfort. Formulated for oral administration as a soluble powder, Carbocisteine Lysine salt monohydrate ensures convenient dosing flexibility. Each sachet contains a precisely calibrated amount of the active ingredient, offering consistent therapeutic efficacy. The typical adult dosage is 750 mg thrice daily, with adjustments made to accommodate individual patient needs by healthcare providers. Quality assurance is at the heart of our corporate ethos. This product conforms to stringent standards, with every batch undergoing rigorous testing to confirm solubility, identification, pH balance, and purity. Our assay guarantees a potency range of 98.0% - 101.0%, ensuring that each dose delivers the expected therapeutic effect. Furthermore, the product's compliance with heavy metal regulations and the meticulous control of residual solvents like ethanol underline our commitment to safety. Moreover, Carbocisteine Lysine salt monohydrate accommodates a broad spectrum of patients, with sensible precautions established for those with a history of gastrointestinal issues or hypersensitivity to its constituents. This product should be used under medical supervision, especially for those with liver or kidney impairments, or during pregnancy and lactation. It is contraindicated in individuals with active peptic ulcers. Storage is straightforward—simply keep the product in a cool, dry environment below 25°C, away from light and moisture, to maintain its integrity. Available in various package sizes, this pharmaceutical offers adaptability for different clinical settings and patient requirements. Choose Carbocisteine Lysine salt monohydrate for dependable respiratory support, backed by the trusted name of Refarmed Chemicals, a company aspiring towards delivering growth in Asia and beyond.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.

Products still subject to third-party patent protection might be available solely for R&D purposes.